Emerging Pathways in COPD: Targeting Inflammation for A Tailored Treatment Approach

Three experts on respiratory diseases give an overview of chronic obstructive pulmonary disease (COPD) and its impact on patients and the healthcare system.

The expert panel offers insights on the concept of extending phenotypes into treatable traits in patients with COPD.

1) Nicola A. Hanania, MD, MS, discusses what we have learned from asthma research on the involvement of type 2 inflammation that is applicable to COPD.

Igor Barjaktarevic, MD, PhD, provides insights on the evolving role of biomarkers in COPD, highlighting the role of eosinophils on informing treatment decisions.

The panel discusses unmet needs in the COPD treatment landscape, highlights the shortcomings of current treatment strategies, and provides insights on diagnostic practices.

Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.

The panel discusses emerging treatment approaches in COPD and reviews the study design and topline results from the BOREAS trial investigating dupilumab.

Experts share perspectives on the future treatment landscape for patients with COPD, highlighting the importance of precision medicine and the remaining unmet needs.

Focusing on evolving therapeutic paradigms for patients with COPD, experts discuss the importance of earlier diagnosis and treatment.

Clinical insights on the relationship between comorbidities in COPD and how multimorbidity plays a role in treatment decisions.

Experts on respiratory diseases discuss the role of primary care providers in the treatment of patients with COPD.

The panel concludes the discussion with key takeaways on the evolving treatment landscape for COPD.